Mutational profiling of low‐grade gliomas identifies prognosis and immunotherapy‐related biomarkers and tumour immune microenvironment characteristics

Low‐grade glioma (LGG) is a heterogeneous tumour with the median survival rate less than 10 years. Therefore, it is urgent to develop efficient immunotherapy strategies of LGG. In this study, we analysed mutation profiles based on the data of 510 LGG patients from the Cancer Genome Atlas (TCGA) data...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Wen‐wen, Ou, Guan‐yong, Zhao, Wei‐jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572778/
https://www.ncbi.nlm.nih.gov/pubmed/34597473
http://dx.doi.org/10.1111/jcmm.16947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572778/
https://www.ncbi.nlm.nih.gov/pubmed/34597473
http://dx.doi.org/10.1111/jcmm.16947

Ejemplares similares